106 results
8-K
EX-99.1
BTTX
Better Therapeutics Inc
11 Mar 24
Regulation FD Disclosure
9:01am
access and scalability Rigorous development incorporating Randomized Controlled Studies representative of diverse populations, backed by Real World … commercialization approach builds on our core advantage of scalability and broad access to offer a high impact population health solution INITIAL FOCUS PAYERS
424B3
BTTX
Better Therapeutics Inc
10 Jan 24
Prospectus supplement
7:01am
of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s … , any other general solicitation or general advertisement.
(g) Access to Information. Such Purchaser acknowledges that it has had the opportunity
8-K
EX-99.1
BTTX
Better Therapeutics Inc
8 Jan 24
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
4:42pm
Russ Johannesson, CEO of Glooko. “This partnership will facilitate access to an important new treatment option for healthcare providers in the Glooko … platform and those we have identified as early adopters for AspyreRx. Glooko’s precision engagement has the potential to accelerate access to AspyreRx
8-K
EX-10.1
cxl4y y125x0a
8 Jan 24
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
4:42pm
424B3
5dfei
28 Dec 23
Prospectus supplement
9:23pm
8-K
EX-10.2
by4eths
13 Dec 23
Entry into a Material Definitive Agreement
5:06pm
8-K
EX-10.1
wm2t7ln
13 Dec 23
Entry into a Material Definitive Agreement
5:06pm
8-K
EX-99.1
8skiq8gu
9 Nov 23
Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
7:03am
PRE 14A
jl9 2ml07
6 Oct 23
Preliminary proxy
4:15pm